Alexander KarpAlexander Karp earned $1B in 2024

In 2024, Dr. Han Ying earned $384.74K in total compensation at Gyre Therapeutics, Inc., including $338.61K salary and $35.00K bonus. Led Gyre Therapeutics, Inc. as CEO for 1 years.

Compensation History

Annual executive compensation data for Dr. Han Ying, including salary, bonuses, and stock awards.

Year

2024

Total Compensation

$384.74K

Salary

$338.61K

Bonus

$35.00K

Other

$11.13K

Salary

$338.61K

Board Justification

These elements (and the amounts of compensation and benefits under each element) were selected because the Company believes they are necessary to help attract and retain executive talent which is fundamental to its success.

Bonus

$35.00K

Board Justification

Mr. Ying was eligible to earn annual cash bonuses targeted at 10% of their respective base salaries. The Compensation Committee approved annual bonuses for Mr. Ying in the amount of $35,000.

Other Compensation

$11.13K

Board Justification

a $2,625 cash retainer for his Board service during 2024 prior to being appointed the Company’s Chief Executive Officer and a Company contribution of $8,500 to Dr. Ying’s account under the Company’s 401(k) plan

Restricted Stock

$0.000 N/A

Board Justification

No vested stock was reported for Dr. Ying in 2024.

Performance Metrics

Such awards are designed to incentivize the named executive officers with a variable level of compensation that is based on performance measures established by the Company’s Compensation Committee that are tied to pre-defined business and personal goals and objectives.

G

Dr. Han Ying

Founder and Ex-CEO of Gyre Therapeutics, Inc.

Education

Ph.D. in Cancer Biology from Stanford University; B.S. and M.S. in Biological Studies from Beijing University.

Field of Expertise

Healthcare & Life Sciences - Immunology

Sector of Economy

Healthcare

Born

January 1, 1964 - 61 years ago

CEO of Gyre Therapeutics, Inc. for

1 year 6 months (Jan 2024 - Aug 2025)

Previous Experience

Director at Gene Corporation; Co-founder and Chief Operating Officer at Base Therapeutics; Chief Technology Officer at Tactiva Therapeutics; Principal Investigator at Maxine Dunitz Neurosurgical Institute.

Holdings

Track Dr. Han Ying's stock holdings and portfolio value over time.

Insider Trading

Dr. Han Ying's recent stock transactions, purchases, and sales filed with the SEC.

No insider trades found for this CEO.

Rivals

Compare Dr. Han Ying with competitor CEOs and industry peers.